Active, not recruitingPhase 2NCT04594798

A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL

Studying Diffuse large B-cell lymphoma with chronic inflammation

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of Rochester
Principal Investigator
Patrick Reagan
University of Rochester
Intervention
Polatuzumab vedotin(drug)
Enrollment
39 enrolled
Eligibility
75 years · All sexes
Timeline
20212026

Study locations (1)

Collaborators

Genentech, Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04594798 on ClinicalTrials.gov

Other trials for Diffuse large B-cell lymphoma with chronic inflammation

Additional recruiting or active studies for the same condition.

See all trials for Diffuse large B-cell lymphoma with chronic inflammation

← Back to all trials